"In a broad-ranging draft guidance published May 2
Post# of 148187
(Total Views: 473)
Posted On: 08/03/2023 3:38:16 PM
"In a broad-ranging draft guidance published May 2, the FDA directs sponsors to communicate with agency staff early on to parse through the specifics of their trial design, and it lays out a roadmap for how to collect data and involve healthcare providers. The FDA received 85 comments on the guidance by the time the comment period closed on Tuesday."
Also of interest:
"stakeholders are largely welcoming the guidance, but are asking the agency to re-examine several aspects, including allowing more flexibility in clinical trial design and loosening the recommendation that participant information be stored at a physical location."
From an article about decentralizing clinical trials. Warning: if you click the link, you will use up one of your 4 free articles. This site is affiliated with Feuerstein so there is NO way I will pay for a subscription.
https://endpts.com/phrma-walgreens-mayo-clini...-guidance/
Also of interest:
"stakeholders are largely welcoming the guidance, but are asking the agency to re-examine several aspects, including allowing more flexibility in clinical trial design and loosening the recommendation that participant information be stored at a physical location."
From an article about decentralizing clinical trials. Warning: if you click the link, you will use up one of your 4 free articles. This site is affiliated with Feuerstein so there is NO way I will pay for a subscription.
https://endpts.com/phrma-walgreens-mayo-clini...-guidance/
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼